Improving Clinical and Economic Outcomes with Personalized Treatment in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bristol-Myers Squibb, AstraZeneca LP, Bayer Healthcare,
Lilly USA, and Merck Sharp & Dohme Corp.

Description:
Lung cancer is the second most common cancer in both men and women, accounting for about 15% of all new cancers and it is expected that there will be about 222,500 new cases of lung cancer in 2019. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. More people die of lung cancer than of colon, breast, and prostate cancers combined. NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Fortunately, more comprehensive information has been gathered regarding tumor characterization which have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Additionally, new treatments have just become available for patients with advanced NSCLC that has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, giving yet another important option in the evolving management of NSCLC.

Upon completion of this activity, participants will be able to:

  • Describe the rationale underlying the use of immune checkpoint inhibition–based strategies for the management of NSCLC

  • Compare and contrast safety and efficacy profiles of current and emerging therapies both alone and in combination in the management of advanced NSCLC

  • Discuss evolving uses for biomarkers to practically inform clinical trial design and decision-making concerning immune checkpoint inhibitor-based treatment strategies in NSCLC

  • Examine recent clinical data on the use of combination immunotherapy in the first-line treatment of patients with TMB-High advanced NSCLC

  • Analyze methods to enable optimal cost management of checkpoint inhibitors to be realized by multiple NSCLC stakeholders including managed care organizations
     

Faculty: Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania

Disclosure:

Dr. Bauml serves as a consultant for AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Genentech, Guardant Health, Janssen, Merck, and Takeda. He has received grant/research support from AstraZeneca, Bayer, Carevive Systems, Incyte, Janssen, Merck, Novartis, and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bristol-Myers Squibb, AstraZeneca LP, Bayer Healthcare,
Lilly USA, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue